Deal Snapshot
ONCOTRACKER ACQUIRES MULTIPLE MYELOMA INTELLECTUAL PROPERTY TO EXPAND DIAGNOSTIC TESTING
Thursday 14 March 2019

California, US-based oncology company OncoTracker, Inc. has agreed to acquire Myeloma and Bone Cancer Research rights to the intellectual property for diagnostic testing of patients with myeloma and bone cancer, the company said.

OncoTracker said the acquisition of two patents offer clinical utility for multiple myeloma patients. OncoTracker, Inc. has exclusive rights to a novel blood biomarker that is the target of several multiple myeloma therapies in clinical development.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 14/03/2019
Target: Myeloma and Bone Cancer Research rights to the intellectual property for diagnostic testing of patients with myeloma and bone cancer
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Financing:
Status: Agreed
Vendor:
Buyer: OncoTracker
Comment:
Terms of the deal were not disclosed

Options